Original Article

Single nucleotide polymorphisms of nucleotide excision repair and homologous recombination repair pathways and their role in the risk of osteosarcoma

Guojun Jin¹, Min Wang², Weida Chen³, Wei Shi⁴, Jiapeng Yin⁵, Wang Gang⁶

ABSTRACT

Objective: To evaluate the influence of polymorphisms in nucleotide excision repair (NER) and homologous recombination repair (HRR) pathways on the development of osteosarcoma patients.

Methods: Genotypes of ERCC1 rs11615 and rs3212986, ERCC2 rs1799793 and rs13181, NBN rs709816 and rs1805794, RAD51 rs1801320, rs1801321 and rs12593359, and XRCC3 rs861539 were conducted by Polymerase Chain Reaction Restriction Fragment Length Polymorphism (PCR-RFLP) assay.

Results: Total 148 osteosarcoma patients and 296 control subjects were collected from Taizhou First People’s Hospital. Conditional logistic regression analyses found that individuals carrying with GA+AA genotype of ERCC2 rs1799793 and GC+CC genotype of NBN rs1805794 were significantly associated with increased risk of osteosarcoma, and the ORs(95%CI) were 1.58(1.03-2.41) and 2.66(1.73-4.08), respectively. We found that GA+AA genotype of ERCC2 rs1799793 or GC+CC genotype of NBN rs1805794 were associated with an increased risk of osteosarcoma in females, with ORs(95%CI) of 2.42(1.20-4.87) and 2.01(1.07-4.23), respectively.

Conclusion: Our results suggest that ERCC2 rs1799793 and NBN rs1805794 polymorphisms were associated with an increased risk for osteosarcoma, which suggests that NER and HRR pathways modulate the risk of developing osteosarcoma.

KEY WORDS: Single Nucleotide Polymorphism, Osteosarcoma, Nucleotide excision repair, Homologous recombination repair.

How to cite this:
Jin G, Wang M, Chen W, Shi W, Yin J, Gang W. Single nucleotide polymorphisms of nucleotide excision repair and homologous recombination repair pathways and their role in the risk of osteosarcoma. Pak J Med Sci 2015;31(2):269-273.
doi: http://dx.doi.org/10.12669/pjms.312.6569

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

INTRODUCTION

Osteosarcoma is a rare bone cancer that has a first peak of incidence in adolescents around 16 years, and a second peak in patients older than 60 years.¹ Osteosarcoma is a kind of disease which caused by complex, multistep, and multifactorial process.² Previous studies have investigated the cancer stem cells and their potential to cause tumors, and genetic factors play an important role in the development of osteosarcoma, and several studies showed that DNA repaired genes are involved in the pathogenesis of this cancer.³⁴ Genetic polymorphisms in DNA repair genes may lead to amino acid substitution and cause differential capacity to repair DNA damage. The
genetic polymorphisms in DNA repair genes have been found to be associated with increased genetic instability and carcinogenesis. In mammalian cells, there were four different DNA repair mechanisms, including nucleotide excision repair (NER), homologous recombination repair (HRR), double-strand break repair (DSBR) and mismatch repair. All these DNA repair pathways are finely regulated for the maintenance of genomic integrity and modulation of repair capacity in response to DNA damage and thus susceptibility to cancer risk.

Excision repair cross-complementation group 2 (ERCC2) gene and excision repair cross complementation group 1 (ERCC1) are parts of an endonuclease complex. More complex DNA damage requires different mechanisms such as HRR for successful repair. In HRR, nibrin (NBN) is part of the complex involved in recognition of DNA damage, while RAD51 recombinase (RAD51) catalyses homologous search and strand invasion with the help of other proteins, including X-ray complementing defective repair in Chinese hamster cells 3 (XRCC3).

Single nucleotide polymorphisms (SNPs) of NER genes have already been associated with development of different cancer types, including osteosarcoma, but all results are not concordant. On the other hand, only a few studies have investigated the influence of HRR SNPs on the development of osteosarcoma. The aim of the present study was to evaluate the influence of polymorphisms in NER and HRR pathways on the development of osteosarcoma patients.

METHODS

Patients: Between January 2012 and January 2014, 148 osteosarcoma patients were diagnosed from Taizhou First People’s Hospital. Osteosarcoma patients were newly diagnosed and histopathologically confirmed independently by two gynecologic pathologists. 296 control subjects were collected from health check center of Taizhou First People’s Hospital, who came to our hospital for medical check up. All the control subjects were confirmed not suffering from osteosarcoma, and had no medical history of any tumor or cancer and no family history of osteosarcoma or other cancers in first-degree relatives. The control subjects were matched to cases by sex and age, and two cases were matched to one case. The study was approved by the Taizhou First People’s Hospital.

Controls were investigated to obtain demographic parameters. For the cases, clinical and pathological information were extracted from the medical records, including tumor stage and location, histological type, and family history of cancer.

Blood samples and genotyping: 5ml peripheral blood was collected from each patient and was kept in -70°C until use. Genomic DNA was isolated from peripheral blood using the TIANamp Blood DNA Kit (Tiangen, Beijing, China) according to the manufacturer’s instructions. Genotypes of ERCC1 rs11615 and rs3212986, ERCC2 rs1799793 and rs13181, NBN rs709816 and rs1805794, RAD51 rs1801320, rs1801321 and rs12593359, and XRCC3 rs861539 were conducted by Polymerase Chain Reaction Restriction Fragment Length Polymorphism (PCR-RFLP) assay. Probes and primers for ERCC1 rs11615 and rs3212986, ERCC2 rs1799793 and rs13181, NBN rs709816 and rs1805794, RAD51 rs1801320, rs1801321 and rs12593359, and XRCC3 rs861539 were designed using Primer 5.0 software (PREMIER Biosoft, Palo Alto, CA). The cycling programme of PCR reaction condition was performed as follows: one initial denaturation step at 5 minutes at 94°C, followed by 35 denaturation cycles of 45s at 94°C, 60s of annealing at 62°C, and 60s of extension at 72°C, and followed by a final extension at 72°C for 10 minutes. In order to perform quality control, genotyping was repeated in 20% samples to check for genotyping accuracy.

Statistical analysis: Continuous variables were expressed as the mean ± SD and analyzed by student t test. Categorical variables were shown as N(%) and analyzed by χ²-test. The χ²-test was performed to verify whether the genotype distributions were in Hardy–Weinberg equilibriums of ERCC1 rs11615 and rs3212986, ERCC2 rs1799793 and rs13181, NBN rs709816 and rs1805794, RAD51 rs1801320, rs1801321 and rs12593359, and XRCC3 rs861539. The association between osteosarcoma group and control group were assessed using unconditional logistic regression, and the results were expressed using odds ratio (OR) and their confidence intervals (CI). All P-values were two sided, and a P-value was regarded as statistically significant when it less than 0.05.

RESULTS

The characteristics of patients with osteosarcoma and controls are shown in Table-I. We did not find significant difference between cases and controls for the frequency-matched variables gender and age at interview (P>0.05). The mean ages of patients with osteosarcoma and controls were 17.7±8.2 and 19.2±5.3 years, respectively. There was no significant
difference between cases and controls in terms of family history of cancer (P>0.05). For the stage of osteosarcoma, 106 (71.62%) were at stage of I-II, and 42 (28.38%) were at stage of III. For the tumor location of these cases, 107 (72.30%) were extremities, and 41 (27.70%) located at other places.

By χ²-test, genotype distributions of ERCC1 rs11615 and rs3212986, ERCC2 rs1799793 and rs13181, NBN rs709816 and rs1805794, RAD51 rs1801320, rs1801321 and rs12593359, and XRCC3 rs861539 in the control subjects were found to be in line with Hardy–Weinberg equilibrium. Conditional logistic regression analyses found that individuals carrying with GA+AA genotype of ERCC2 rs1799793 were significantly associated with increased risk of osteosarcoma when compared with GG genotype (OR=1.58, 95%CI=1.03-2.41). Moreover, individuals carrying GC+CC genotype of NBN rs1805794 were correlated with a heavy enhanced risk of osteosarcoma when compared

### Table I: Characteristics of patients with osteosarcoma and controls.

| Characteristics                  | Cases | %   | Controls | %   | OR(95%CI) | P value |
|----------------------------------|-------|-----|----------|-----|-----------|---------|
| Gender                           |       |     |          |     |           |         |
| Male                             | 91    | 61.49 | 181      | 61.15 | 1.0(Ref.) |         |
| Female                           | 57    | 38.51 | 115      | 38.85 | 0.98(0.64-1.51) | 0.95 |
| Mean age, years                  |       |     |          |     |           |         |
| <20                              | 87    | 58.78 | 164      | 55.41 | 1.0(Ref.) |         |
| ≥20                              | 61    | 41.22 | 132      | 44.59 | 0.87(0.57-1.32) | 0.5 |
| Family history of cancer         |       |     |          |     |           |         |
| Positive                         | 35    | 23.65 | 63       | 21.28 | 1.0(Ref.) |         |
| Negative                         | 113   | 76.35 | 233      | 78.72 | 0.87(0.53-1.44) | 0.57 |
| Stage                            |       |     |          |     |           |         |
| I-II                             | 106   | 71.62 |          |     |           |         |
| III                              | 42    | 28.38 |          |     |           |         |
| Histological type                |       |     |          |     |           |         |
| Osteoblastic                     | 48    | 32.43 |          |     |           |         |
| Chondroblastic                   | 70    | 47.3  |          |     |           |         |
| Other                            | 30    | 20.27 |          |     |           |         |
| Tumor location                   |       |     |          |     |           |         |
| Extremities                      | 107   | 72.3  |          |     |           |         |
| Other                            | 41    | 27.7  |          |     |           |         |

### Table II: Genotype distribution of ten SNPs in NER and HRR pathways between cases and controls.

| Gene              | Genotype | Cases | %   | Controls | %   | OR(95%CI)1 | P value |
|-------------------|----------|-------|-----|----------|-----|------------|---------|
| ERCC1 rs11615     | TT       | 63    | 42.57 | 135      | 45.3 | 1.0(Ref.) | -       |
|                   | TC+CC    | 85    | 57.43 | 163      | 54.7 | 1.12(0.74-1.70) | 0.58 |
| ERCC1 rs3212986   | GG       | 79    | 53.38 | 169      | 56.71 | 1.0(Ref.) | -       |
|                   | GA+AA    | 69    | 46.62 | 129      | 43.29 | 1.14(0.75-1.73) | 0.5 |
| ERCC2 rs1799793   | GG       | 84    | 56.76 | 201      | 67.45 | 1.0(Ref.) | -       |
|                   | GA+AA    | 64    | 43.24 | 97       | 32.55 | 1.58(1.03-2.41) | 0.03 |
| ERCC2 rs13181     | AA       | 86    | 58.11 | 181      | 60.74 | 1.0(Ref.) | -       |
|                   | AC+CC    | 62    | 41.89 | 117      | 39.26 | 1.12(0.73-1.70) | 0.59 |
| NBN rs709816      | GG       | 55    | 37.16 | 115      | 38.59 | 1.0(Ref.) | -       |
|                   | GC+CC    | 93    | 62.84 | 183      | 61.41 | 1.06(0.69-1.63) | 0.78 |
| NBN rs1805794     | GG       | 52    | 35.14 | 127      | 42.62 | 1.0(Ref.) | -       |
|                   | GC+CC    | 96    | 64.86 | 171      | 57.38 | 2.66(1.73-4.08) | <0.001 |
| RAD51 rs1801320   | GG       | 101   | 68.24 | 213      | 71.48 | 1.0(Ref.) | -       |
|                   | GC+CC    | 47    | 31.76 | 85       | 28.52 | 1.17(0.74-1.82) | 0.48 |
| RAD51 rs1801321   | GG       | 88    | 59.46 | 187      | 62.75 | 1.0(Ref.) | -       |
|                   | GT+TT    | 60    | 40.54 | 111      | 37.25 | 1.15(0.75-1.75) | 0.5 |
| RAD51 rs12593359  | TT       | 49    | 33.11 | 105      | 35.23 | 1.0(Ref.) | -       |
|                   | TG+GG    | 99    | 66.89 | 193      | 64.77 | 1.10(0.71-1.71) | 0.66 |
| XRCC3 rs861539    | CC       | 77    | 52.03 | 173      | 58.05 | 1.0(Ref.) | -       |
|                   | CT+TT    | 71    | 47.97 | 125      | 41.95 | 1.28(0.84-1.93) | 0.23 |

1Adjusted for sex, age and family history of cancer.
with GG genotype, and the OR(95%CI) was 2.66(1.73-4.08). However, we did not find significant association between ERCC1 rs11615 and rs3212986, ERCC2 rs13181, NBN rs709816, RAD51 rs1801320, rs1801321 and rs12593359, and XRCC3 rs861539 and risk of osteosarcoma.

Moreover, we conducted stratification analysis on the association between ERCC2 rs1799793 and NBN rs1805794 and demographic characteristics in osteosarcoma patients. We found that GA+AA genotype of ERCC2 rs1799793 and GC+CC genotype of NBN rs1805794 were associated with increased risk of osteosarcoma, and the ORs(95%CI) were 2.42(1.20-4.87) and 2.01(1.07-4.23), respectively.

**DISCUSSION**

In this hospital-based case-control study, we investigated the role of ten SNPs in NER and HRR pathways about the risk of osteosarcoma. Since there is increasing evidence that genetic variation leads to different DNA repair capacities in the human population, such common polymorphisms can play a role in an individual’s genetic susceptibility to cancer.\(^{16}\) Mutations in DNA repaired gene may lead to decrease or loss of its DNA repair capacity and confer the variation in susceptibility to diverse malignant tumors among individuals. Many studies have indicated that polymorphisms in DNA repair genes may modify the risk for cancer, such as esophageal cancer, breast cancer, glioma and prostate cancer.\(^{17-21}\) While few studies reported the role of DNA repair genes and development of osteosarcoma.\(^{21}\)

We also found that ERCC2 rs1799793 and NBN rs1805794 may be associated with carcinogenesis of osteosarcoma. GA+AA genotype of ERCC2 rs1799793 and GC+CC genotype of NBN rs1805794 were associated with increased risk of osteosarcoma, but that gene polymorphisms of ERCC1 rs11615 and rs3212986, ERCC2 rs13181, NBN rs709816, RAD51 rs1801320, rs1801321 and rs12593359, and XRCC3 rs861539 and risk of osteosarcoma.

Moreover, we conducted stratification analysis on the association between ERCC2 rs1799793 and NBN rs1805794 and demographic characteristics in osteosarcoma patients. We found that GA+AA genotype of ERCC2 rs1799793 and GC+CC genotype of NBN rs1805794 were associated with increased risk of osteosarcoma, and the ORs(95%CI) were 2.42(1.20-4.87) and 2.01(1.07-4.23), respectively.

### Table-III: Stratification analysis on the association between rs699947 and rs2010963 and demographic characteristics in osteosarcoma risk.

| Variables                  | ERCC2 rs1799793 | NBN rs1805794 |
|----------------------------|-----------------|---------------|
|                            | Cases/Controls  | Cases/Controls|
| **Gender**                 |                 |               |
| Male                       | 58/124          | 33/57         |
| Female                     | 26/77           | 31/38         |
| **Age**                    |                 |               |
| <20                        | 53/34           | 119/45        |
| ≥20                        | 31/82           | 30/50         |
| **Family history of cancer** |                |               |
| Positive                   | 11/28           | 24/35         |
| Negative                   | 73/173          | 40/60         |

Table-III: Stratification analysis on the association between rs699947 and rs2010963 and demographic characteristics in osteosarcoma risk.
rs1805794 polymorphisms were associated with osteosarcoma risk, more biological background data are needed to explain our results. The current finding might involve gene-to-environment interactions, which were not explored in the present study. Second, the sample size of this study is relatively small, which may not have enough statistical power to explore the real association. Third, this is a hospital based case control study, so the selection bias cannot be ignored and the subjects may not be representative of the general population. Finally, these results should be interpreted with caution because the population was only from China, which reduces the possibility of confounding from ethnicity, so it does not permit extrapolation of the results to other ethnic groups.

In conclusion, our study is, to our knowledge, the first to examine prospectively an increased risk role of ten SNPs in DNA repair pathway in osteosarcoma susceptibility, and we found that ERCC2 rs1799793 and NBN rs1805794 polymorphisms modulate the risk of developing osteosarcoma. Additional studies are greatly needed to confirm this finding.

REFERENCES

1. Ritter J, Bielack SS. Osteosarcoma. Ann Oncol. 2010;21(Suppl 7):vii320-25. doi: 10.1093/annonc/mdq276.
2. Ottaviani G, Jaffe N. The etiology of osteosarcoma. Cancer Treat Res. 2009;152:15-32. doi: 10.1007/978-1-4419-0284-9_2.
3. Goričar K, Erculi N, Zadel M, Dolzan V. Genetic polymorphisms in homologous recombination repair genes in healthy Slovenian population and their influence on DNA damage. Radiol Oncol. 2012;46(1):46-53. doi: 10.2478/ro-2012-0007.
4. Goričar K, Kovač V, Jazbec J, Zakotnik B, Lamovec J, Dolzan V. Influence of the folate pathway and transporter polymorphisms on methotrexate treatment outcome in osteosarcoma. Pharmacogenet Genomics. 2014;24(10):514-21. doi: 10.1097/FCG.0000000000000833.
5. de Boer JG. Polymorphisms in DNA repair and environmental interactions. Mutat Res. 2002;509:201-10.
6. Yu Z, Chen JF, Ford BN, Brackley ME, Glickman BW. DNA repair systems: an overview. Environ Mol Mutagen. 1999;33(1):3-20. doi:10.1002/(SICI)1098-2280(1999)33:1<3::AID-EM2>3.0.CO;2-1.
7. Christmann M, Tomicic MT, Roos WP, Kaina B. Mechanisms of human DNA repair: an update. Toxicology. 2003;193:3-34. doi: 10.1016/s0300-483x(03)00287-7.
8. Willers H, Dahm-Daphi J, Powell SN. Repair of radiation damage to DNA. Br J Cancer. 2004;90(7):1297-1301. doi: 10.1038/sj.bjc.6601729.
9. Wessendorf P, Viigj B, Nussenweig A, Digweeda M. Deficiency of the DNA repair protein nibrin increases the basal but not the radiation induced mutation frequency in vivo. Mutat Res Fundam Mol Mech Mutagen. 2014;769:11-16. doi:10.1016/j.mrfmmm.2014.07.001.
10. Liu C, Yin Q, Hu J, Weng J, Wang Y. Quantitative assessment of the association between XPG Asp1104His polymorphism and bladder cancer risk. Tumour Biol. 2014;35(2):1203-1209. doi: 10.1007/s13277-013-1161-9.
11. Li X, Xu J, Yang X, Wu Y, Cheng B, Chen D, et al. Association of single nucleotide polymorphisms of nucleotide excision repair genes with laryngeal cancer risk and interaction with cigarette smoking and alcohol drinking. Tumour Biol. 2014;35(5):4695-4665. doi: 10.1007/s13277-014-1610-0.
12. Lu B, Li J, Gao Q, Yu W, Yang Q, Li X. Laryngeal cancer risk and common single nucleotide polymorphisms in nucleotide excision repair pathway genes ERCC1, ERCC2, ERCC3, ERCC4, ERCC5 and XPA. Gene. 2014;542(1):64-68. doi: 10.1016/j.gene.2014.02.043.
13. Zhi LQ, Ma W, Zhang H, Zeng SX, Chen B. Association of RECQL5 gene polymorphisms and osteosarcoma in a Chinese Han population. Tumour Biol. 2014;35(4):3255-3259. doi: 10.1007/s13277-013-1425-4.
14. He J, Wang J, Wang D, Dai S, Yu T, Chen P, et al. Association analysis between genetic variants of MDM2 gene and osteosarcoma susceptibility in Chinese. Endocr J. 2013;60(11):1215-20.
15. Wang Z, Wen P, Luo X, Fang X, Wang Q, Ma F, et al. Association of the vascular endothelial growth factor (VEGF) gene single-nucleotide polymorphisms with osteosarcoma susceptibility in a Chinese population. Tumour Biol. 2014;35(4):3605-3610. doi: 10.1007/s13277-014-1475-7.
16. Berwick M, Vines P. Markers of DNA repair and susceptibility in humans: an epidemiological review. J Natl Cancer Inst. 2000;91:874-897. doi: 10.1093/ijc/92.11.874.
17. Zhu ML, He J, Wang M, Sun MH, Jio L, Wang X, et al. Potentially functional polymorphisms in the ERCC2 gene and risk of Esophageal Squamous Cell Carcinoma in Chinese populations. Sci Rep. 2014;4:6281. doi: 10.1038/srep06281.
18. Wang T, Wang H, Guo H, Yang S, Zhu G, Guo H, et al. Polymorphisms in the DNA Repair Gene ERCC2/XPD and Breast Cancer Risk: A HapMap-Based Case-Control Study Among Han Women in a Chinese Less-Developed Area. Genet Test Mol Biomarkers. 2014;18(10):703-10. doi: 10.1089/gtmb.2014.0028.
19. Huang LM, Shi X, Yan DF, Zheng M, Deng YJ, Zeng WC, et al. Association between ERCC2 polymorphisms and glioma risk: a meta-analysis. Asian Pac J Cancer Prev. 2014;15(11):4417-4422. doi: 10.7314/APJCP.2014.15.11.4417.
20. Zhou C, Xie LP, Lin YW, Yang K, Mao QQ, Cheng Y. Susceptibility of XPD and hOGG1 genetic variants to prostate cancer. Biomed Rep. 2013;1(4):679-683. doi: 10.3892/br.2013.123.
21. Zhi LQ, Ma W, Zhang H, Zeng SX, Chen B. Association of RECQL5 gene polymorphisms and osteosarcoma in a Chinese Han population. Tumour Biol. 2014;35(4):3255-3259. doi: 10.1007/s13277-013-1425-4.
22. Spitz MR, Wu X, Wang Y, Wang LE, Shete S, Amos CI, et al. Modulation of nucleotide excision repair capacity by RECQL5 gene polymorphisms and osteosarcoma in a Chinese population. Tumour Biol. 2014;35(4):3605-3610. doi: 10.1007/s13277-014-1475-7.
23. Wang T, Wang H, Guo H, Yang S, Zhu G, Guo H, et al. Polymorphisms in the DNA Repair Gene ERCC2/XPD and Breast Cancer Risk: A HapMap-Based Case-Control Study Among Han Women in a Chinese Less-Developed Area. Genet Test Mol Biomarkers. 2014;18(10):703-10. doi: 10.1089/gtmb.2014.0028.
24. Berwick M, Vines P. Markers of DNA repair and susceptibility in humans: an epidemiological review. J Natl Cancer Inst. 2000;91:874-897. doi: 10.1093/ijc/92.11.874.
25. Zhu ML, He J, Wang M, Sun MH, Jio L, Wang X, et al. Potentially functional polymorphisms in the ERCC2 gene and risk of Esophageal Squamous Cell Carcinoma in Chinese populations. Sci Rep. 2014;4:6281. doi: 10.1038/srep06281.